MS and Demyelinating Disorders

Here's what is coming soon to NeurologyLive®.

The registered dietitian and founder of MS Bites spoke on changes in symptom care for patients with MS, as well as the sustained benefits of telehealth. [WATCH TIME: 2 minutes]

Neurology News Network for the week ending January 1, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 31, 2021.

Take a look back at some of the most-viewed, top video series with key experts in neurology and their in-depth discussions, part of NeurologyLive®'s Year in Review.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Majersik, MD, MS.

As part of NeurologyLive®'s Year in Review, take a look at some of the most engaging conversations the team has had with experts in neurology this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the most listened to and engaging conversations from the Mind Moments™ podcast from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the biggest FDA approvals and decisions from this past year.

The research assistant professor at the Buffalo Neuroimaging Analysis Center detailed the improvements the current batteries for detecting cognitive impairment in MS need. [WATCH TIME: 3 minutes]

Mona Bostick, RDN, LDN, MSCS, reflected on the past year in multiple sclerosis care, offering her opinion on the importance of diet and science-based nutritional approaches.

These news stories were among the most-discussed conversations in the field and were often included in NeurologyLive®'s coverage in multiple sclerosis.

As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

Neurology News Network for the week ending December 25, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.

The chief medical officer of Cognetivity Neurosciences outlined the benefits a new integrated assessment has for clinicians and patients with dementias and multiple sclerosis. [WATCH TIME: 4 minutes]

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided insight on a new study that looks at the connection between brain structure and cognitive decline in patients with multiple sclerosis and other neurodegenerative disorders.

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed a recently awarded grant to determine which brain structures are responsible for cognitive decline in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive®.

These findings have clinical implications for the diagnosis of AQP4-NMOSD and in helping clinicians differentiating it from other demyelinating diseases such as MOGAD.

Amy Kunchok, MD, staff neurologist at the Mellen Center for Multiple Sclerosis and Research at Cleveland Clinic, discussed a recent talk she gave that highlighted the different phenotypes of AQP-IgG NMOSD and MOGAD.

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

The staff neurologist at the Cleveland Clinic Mellen Center for Multiple Sclerosis outlined key findings from her talk at a recent Institutional Perspectives in Neurology: Multiple Sclerosis event. [WATCH TIME: 3 minutes]

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

The FDA has set a prescription drug user fee act goal date of September 28, 2022, for the investigational treatment from TG Therapeutics.

Chris Kalafatis, MD, MRCPsych, discussed a new tool, the Integrated Cognitive Assessment, developed by Cognetivity, and its potential for patients with dementias and multiple sclerosis.